"Relyvrio: ALS Drug Failure Sparks Market Withdrawal Concerns"
TL;DR
Amylyx Pharmaceuticals' drug Relyvrio, approved for ALS treatment in 2022, has failed to outperform a placebo in a pivotal study, prompting discussions about its removal from the market and raising questions about the FDA's decision to authorize it. The disappointing results have left ALS patients, advocates, and researchers grappling with the next steps in light of the drug's lack of efficacy, highlighting the challenges of regulatory leniency for treatments of devastating, incurable diseases.
- Amylyx ALS drug failure raises questions and concerns STAT
- ALS drug fails large clinical trial and may be withdrawn from market CNN
- A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market The New York Times
- Amylyx ALS drug fails large clinical trial - STAT STAT
- ALS treatment Relyvrio fails trial, may be withdrawn from market ALS News Today
Want the full story? Read the original reporting
Read on STAT